Highlights

  • Aroa Biosurgery (ASX:ARX) received US reimbursement clarity following CMS plans to maintain outpatient skin-substitute payment rates into 2027.
  • Symphony is being positioned for chronic wound-care applications including diabetic foot ulcers and venous leg ulcers.
  • FY26 Revenue increased 23% to NZ$103.9 million, supported by Myriad growth.
  • FY27 Investment plans focus on expanding sales capability and Symphony commercial infrastructure.

Aroa Biosurgery (ASX:ARX) has gained greater visibility around the US reimbursement environment for skin-substitute products as it prepares to expand commercial activity for Symphony, its wound-care product.

The company’s latest update highlights the importance of reimbursement stability in the US healthcare market, where payment changes can significantly influence product adoption and commercial outcomes.

What Happened?

On 14 July 2026, Aroa Biosurgery (ASX:ARX) advised that the United States Centers for Medicare & Medicaid Services (CMS) had proposed maintaining the calendar-year 2027 payment framework for skin-substitute products used in hospital outpatient departments and ambulatory surgical centres.

The proposed framework would retain a blended payment rate of US$127.14 per square centimetre, which was introduced from 1 January 2026.

CMS indicated that it intends to review 2026 claims data before making further changes.

Aroa highlighted the relevance of the reimbursement environment for Symphony, its skin-substitute product designed for hard-to-heal wounds including diabetic foot ulcers and venous leg ulcers.

The outpatient reimbursement framework does not apply to Myriad, Aroa’s soft-tissue reconstruction product used in inpatient hospital settings.

Why It Matters

Reimbursement conditions are an important Factor in the adoption of medical technology products in the United States.

The introduction of a blended payment rate in 2026 changed the Economics of the outpatient skin-substitute market by reducing previous pricing differences between products.

Aroa believes the revised environment may favour products supported by clinical evidence and sustainable pricing structures.

The stability of the reimbursement framework provides hospitals and clinicians with greater visibility when assessing wound-care products.

Aroa has also developed a direct sales presence in outpatient settings, aligning its commercial structure with the changing market environment.

The Numbers

Aroa reports financial results in New Zealand dollars.

For FY26, the company reported revenue of NZ$103.9 million, representing 23% growth compared with the prior year.

Myriad revenue increased 54% to NZ$49.5 million, becoming the company’s largest individual product line.

Gross Margin was 85.5%, while normalised Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) was NZ$12.6 million.

Aroa ended FY26 with NZ$27.1 million in cash and no debt.

Direct-channel sales represented 59% of product revenue.

For FY27, Aroa is targeting revenue of NZ$115 million to NZ$125 million, representing growth of 13% to 23%, while EBITDA guidance is NZ$8 million to NZ$11 million due to planned investment in sales capability and Symphony infrastructure.

The Bigger Picture

Aroa’s technology platform is based on extracellular matrix material derived from ovine forestomach tissue, designed to support tissue regeneration.

The platform supports both Myriad in surgical reconstruction and Symphony in chronic wound care applications.

Chronic wound treatment remains a significant healthcare area due to conditions such as diabetic foot ulcers and venous leg ulcers.

The company’s opportunity depends on demonstrating clinical effectiveness, achieving product adoption and competing within a changing reimbursement environment.

The reimbursement reset may create opportunities for companies with established clinical evidence, although competitive pressure remains a factor.

The Bull Case

The positive case for Aroa Biosurgery (ASX:ARX) is based on continued Myriad growth, Symphony commercial expansion and improved reimbursement visibility.

Myriad has delivered revenue growth and remains the company’s largest product contributor.

Symphony provides an additional growth opportunity in outpatient wound care, supported by a more stable reimbursement environment.

Aroa’s investment in direct sales infrastructure may improve its ability to engage with hospitals and clinicians.

If Symphony adoption increases and clinical data supports its use, the company could expand its position within the wound-care market.

Risks Investors Should Understand

Aroa Biosurgery (ASX:ARX)’s Business faces risks including reimbursement changes, commercial execution, clinical adoption, competition and currency exposure.

The CMS reimbursement framework remains subject to further review and future changes could affect product economics.

Symphony’s commercial rollout is still developing, and product adoption depends on clinician acceptance, hospital decisions and evidence supporting its use.

FY27 EBITDA guidance is lower than FY26 as the company increases investment in sales resources and commercial infrastructure.

The company’s exposure to the United States market also creates sensitivity to healthcare policy changes and exchange-rate movements.

What Comes Next?

The next key milestone is publication of randomised controlled trial results for Symphony, which Aroa expects during the third quarter of FY27.

Investors will monitor the final CMS reimbursement decision, Symphony adoption rates, Myriad sales performance and whether increased investment translates into revenue growth.

The company’s ability to balance near-term investment with future profitability will remain a key focus.

Conclusion

Aroa Biosurgery (ASX:ARX) has gained greater clarity around the US reimbursement environment while preparing for broader commercial activity with Symphony.

The reimbursement update reduces uncertainty in a key market, while Myriad continues to provide the company’s established revenue base.

However, the longer-term opportunity depends on Symphony adoption, clinical validation, reimbursement stability and execution of the company’s planned commercial investment.